A Companion Diagnostic Study to Develop Circulating Exosomes as Predictive Biomarkers for the Response to Immunotherapy in Renal Cell Carcinoma - Trial NCT05705583
Access comprehensive clinical trial information for NCT05705583 through Pure Global AI's free database. This phase not specified trial is sponsored by Zhejiang Cancer Hospital and is currently Recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Zhejiang Cancer Hospital
Timeline & Enrollment
N/A
Jan 01, 2023
Dec 31, 2025
Primary Outcome
The correlation between the circulating exosomes levels and the tumor responsiveness
Summary
Immune checkpoint inhibitors targeting PD-1 or PD-L1 have been developed and clinical trials
 showning better response in unselected patients with metastatic renal cell carcinoma (RCC).
 At the moment, no clear biomarker exists to accurately predict anti-PD1/PDL1 RCC
 responsiveness. The objective of this study is to develop and evaluate the utility of
 circulating exosomes as companion diagnostic biomarker for predicting response to
 immunotherapy in patients with RCC.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05705583
Non-Device Trial